Exabis Library
Welcome to the e-CCO Library!
P662 Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P662: A retrospective claims analysis on the prevalence and incidence of ulcerative colitis in Germany and the frequency of advanced therapy use
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P662: Colorectal Cancer in Patients with Ulcerative Colitis: A National Cohort Study between 1991-2020
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P662: Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P662: Remission to vedolizumab is not higher in TNF-naïve compared with TNF-pre-treated patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P662: Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P662: Transmural healing evaluated by magnetic resonance enterography in paediatric Crohn’s disease patients under maintenance treatment with biologics
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P663 Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P663: Long-term follow up in IBD: 10-year observational study of a UK IBD cohort.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P663: Mild COVID-19 disease and breakthrough cases among children with inflammatory bowel disease: An update from an international registry
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P663: Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P663: Primary prevention of post-operative recurrence of Crohn’s disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P663: Switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P663: The effect of vitamin D deficiency, and its correction, on healthcare utilisation among patients with inflammatory bowel disease (IBD)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: A real-life experience of a single-centre cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P664: Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P664: Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P664: Association between pharmacologic loss of response profile of anti-TNF and clinical outcome with vedolizumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P664: Bidirectional association between inflammatory bowel disease and psoriasis in a pediatric population: A nationwide insurance claim data analysis in South Korea.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P664: SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM